Skip to main content

Table 1 Patient and Treatment Characteristics

From: Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Variable n %
No. of Patients 16  
Treatment Sessions 18  
No. of Lesions 40  
F/U from RT (months)
 Median (range) 13.2 (0.1–55.5)  
F/U from Brain Metastases Diagnosis (months)
 Median (range) 68.6 (16.5–249)  
Age at time of RT
 Median (range) 56 (40–85)  
KPS
 100 2 13%
 90 10 63%
 80 4 25%
Lesions Treated Per Patient
 Median (range) 2 (1–6)  
Receptors
 HR+/HER2+ 10 63%
 HR−/HER2+ 6 38%
Concurrent Therapy with SRS
 None 9 50%
 Chemotherapy 1 5%
 TP 2 11%
 Chemotherapy + TP 2 11%
 ET 2 11%
 ET + TKI + TP 1 5%
 ET + TP 1 5%
  1. Abbreviations: F/U = follow up, RT = radiation therapy, KPS = Karnofsky performance status, TKI = tyrosine kinase inhibitor, ET = endocrine therapy, TP = trastuzumab and/or pertuzumab, HR = hormone receptor, SRS = stereotactic radiosurgery